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Abstract Serological biomarkers which enable quick and
reliable diagnosis or measurement of the extent of irre-
versible brain injury early in the course of stroke are
eagerly awaited. Neurofilaments (Nf) are a group of pro-
teins integrated into the scaffolding of the neuronal and
axonal cytoskeleton and an established biomarker of neuro-
axonal damage. The Nf heavy chain (NfHSMI35) was
assessed together with brain-specific astroglial proteins
GFAP and S100B in hyperacute stroke (6 and 24 h from
symptom onset) and daily for up to 6 days. Twenty-two
patients with suspected stroke (median NIHSS 8) were
recruited in a prospective observational study. Evidence for
an ischaemic or haemorrhagic lesion on neuroimaging was
found in 18 (ischaemia n = 16, intracerebral haemorrhage
n = 2). Serum NfHSMI35 levels became detectable within
24 h post-stroke (P \ 0.0001) and elevated levels persisted
over the study course. While GFAP was not detectable
during the entire course, S100B levels peaked at the end of
the observation period. The data indicate that significant in
vivo information on the pathophysiology of stroke may be
obtained by the determination of NfHSMI35. Further studies
are required to evaluate whether NfHSMI35 in hyperacute
stroke reflects the extent of focal ischaemic injury seen on
neuroimaging or is a consequence of more diffuse neuro-
axonal damage.
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Introduction
Stroke is a serious condition resulting in significant mor-
tality and long-term morbidity. Ischaemia is associated
with reduction in oxygen and glucose supply within the
central nervous system (CNS). When blood flow falls
below a critical threshold, a cascade of biochemical reac-
tions generating excitotoxicity, oxidative stress, inflam-
mation, and cell death is triggered, leading to tissue
infarction [1]. This detrimental process is associated with
release of different cell-type specific proteins including
calcium-binding protein S100B, glial fibrillary astrocytic
protein (GFAP) and neurofilaments (Nf) into extracellular
fluids (ECF). From the ECF, these proteins diffuse to the
CSF and peripheral blood, where they can be quantified
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[2]. Increased attention has been directed to establish-
ing the measurement of these molecules as a tool to
assist in diagnosis, selection of treatments, assessment of
the efficacy of treatments, and prediction of outcome of
stroke [3].
In brief, GFAP is a brain-specific astrocytic intermediate
filament protein, which is released upon cellular disinte-
gration and degradation of the cytoskeleton. The determi-
nation of GFAP in the time window of 2 and 6 h after
stroke may be helpful in the distinction of ischaemic from
haemorrhagic stroke. Dvorak et al. reported that patients
with intracerebral haemorrhage had significantly elevated
GFAP levels in this period, whereas GFAP levels remain
below the detection limit in ischaemic stroke [4]. S100B is
mainly found in astrocytes and other sources include oli-
godendrocytes, microglia and neurons. Concentrations in
cerebrospinal fluid (CSF) were found to be up to 60 times
higher than in serum [5]. Importantly, previous reports
indicated that S100B serum values correlate with final
infarct volume when determined beyond 24 h after symp-
tom onset [6–8]. In contrast to the multiple sources of
S100B, neurofilaments, a group of proteins integrated into
the scaffolding of the neuronal and axonal cytoskeleton, are
specific to and abundant in the neuro-axonal compartment
[9]. Both neurofilament light (NfL, 68 kDa) and heavy
chains (NfH, 190–210 kDa) can be measured in CSF [10].
So far, quantification from serum is possible for NfH only.
Significant positive associations were found for blood NfH
levels and clinical severity, volume of the ischaemic ter-
ritory and outcome when assessed 3 weeks after symptom
onset [11]. There is no linear correlation for CSF and serum
concentration. Assessment of S100B and NfH concentra-
tions in ischaemic stroke revealed that CSF but not serum
concentrations correlated positively with outcome on the
modified Rankin scale (mRS) [5]. But samples were taken
relatively late in this study (median 3 days, range
1–15 days).
An important question for future treatment approaches
is the time course of irreversible neuronal damage and the
potential to quantify the extent. Not all incidents of
oxygen and glucose deprivation will lead to irreversible
brain injury [12]. Indeed, ischaemic lesions visualized by
CT and even multimodal magnetic resonance imaging
(MRI) in the acute phase (\24 h of symptom onset) do
not necessarily reflect the final infarct volume [13].
Moreover, milder ischaemic events will only lead to
temporary neuronal dysfunction and may be even asso-
ciated with preconditioning and increase resistance
towards irreversible damage [14]. Hence, a biomarker
identifying the extent of irreversible neuro-axonal injury
in the critical early phase is of utmost importance. Here,
we aimed at evaluating the earliest consequences of
stroke by studying sequential serum samples with a panel
of three biomarkers within 24 h of symptom onset and the
subsequent period of 6 days.
Materials and Methods
Patients and Sample Collection
The study was approved by the local ethics committee.
Written informed consent was obtained from the patients
and when this was not possible from the next family
member.
Patients admitted to the Accident and Emergency
Department of University College London Hospital
(UCLH) with a suspected acute cerebrovascular event with
onset of symptoms \24 h prior to assessment were eval-
uated prospectively over an 8 month period. Twenty-two
patients were recruited and peripheral-venous blood was
obtained upon arrival and daily between 9:00 and 10:00
a.m. over a 6-days period. The tube was left standing at
room temperature for 30 min to allow blood clotting. The
sample was then centrifuged at 1,500g for 10 min, and
serum was removed and coded aliquots were stored at -
80C. The clinical assessment consisted of the NIH stroke
scale (NIHSS), the Glasgow coma scale and basic vital
signs including blood pressure, temperature and peripheral
oxygen saturation. Further parameters monitored were
haematocrit and blood pressure. All patients were exam-
ined with a brain CT scan. Twenty patients presenting to
the same Accident and Emergency Department without
evidence for neurological disease were recruited as
controls.
Quantification of NfH, S100B and GFAP Levels
Serum NfHSMI35 levels were measured using an enzyme-
linked immunoassay, as described previously [10, 15]. The
mouse monoclonal antibody SMI35 (IgG) was originally
purchased from Sternberger Monoclonals Inc., and is now
available through Covance Research Products (Berkeley,
CA, USA). The secondary and tertiary antibodies used
were the rabbit polyclonal anti-NfH IgG (Sigma, St. Lous,
MO; N 4142) and the horseradish peroxidase (HRP)-
labelled swine polyclonal anti-rabbit IgG (DAKO,
Copenhagen, Denmark). Adhering to the nomenclature
previously set up, we indicate the captured antibodies used
for NfH quantification in superscript (NfHSMI35 for
SMI35). Serum S100B and GFAPSMI26 levels were deter-
mined with an ELISA as described before [16, 17]. The
detection limit for the NfHSMI35 assay is 0.01 ng/mL. The
detection limits for GFAPSMI26 is 5 pg/mL and for S100B
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7 pg/mL. The analyst was blinded to all clinical informa-
tion and measurements were done in duplicates.
Statistical Analysis
Statistical analysis was carried out using Graph Pad Prism
Software Version 5.0 (San Diego, CA, USA). The non-
parametric Mann–Whitney test was used for comparison of
controls and stroke at baseline (\24 h). The Kruskal–
Wallis test with Dunn’s multiple post-hoc comparison was
used to compare dynamics of NfHSMI135, S100B and
GFAPSMI26 serum levels in the first 6 days after stroke
onset. Two sided tests were used and a P value\0.05 was
accepted as significant.
Results
Stroke Patients and Controls
Radiological evidence for stroke was found in 18 patients.
Ischaemic stroke was diagnosed in the majority (n = 16),
whereas haemorrhagic stroke was the cause of neurological
symptoms in two. In the remaining four subjects no vas-
cular or structural pathology was seen on MRI and lead to
exclusion from further analysis. None of the patients with
ischemic stroke was treated with intravenous alteplase. The
baseline characteristics of the 18 stroke patients and con-
trols are shown in Table 1.
Serum Levels of NfHSMI35, S100B and GFAPSMI26
in Acute Stroke and Controls
Hyperacute stroke was defined as onset of stroke symptoms
\24 h before assessment and samples from 15 patients
were available within this time period. NfHSMI35 levels
were significantly higher in hyperacute stroke (median
0.13 ng/mL, range 0–0.17) compared to the control group
(median 0 ng/mL, range 0–0.05; P \ 0.0001) (Fig. 1).
Median S100B levels in hyperacute stroke were
(0.03 ng/mL, range 0–0.33) were lower than in controls
(0.09 ng/mL, range 0.05–0.32). The S100B levels in stroke
patients were not statistically different from controls.
GFAPSMI26 serum levels were below the detection limit in
all the samples. Neither NfHSMI35 nor S100B levels cor-
related with age or NIHSS scores.
Time Course of NfHSMI35 and S100B in Acute Stroke
The time course of the three biomarkers levels over 6 days
following stroke onset is shown in Table 2. Patients with
confirmed stroke on neuroimaging had increased NfHSMI35
levels already within 6 h of symptom onset. The increase
persisted over the 6 days course and peaked at day 4 but
changes did not reach statistical significance compared to
other time points. The increase of S100B, however, was
delayed and started 3 days and peaked at 6 days post
stroke. Differences were not statistically significant. GFAP
remained below the detection limit in all stroke patients
over the entire time course.
Table 1 Baseline characteristics of the control and stroke cohort
Characteristic Control Stroke Stroke subtype
Ischaemic Haemorrhagic
Age, year (mean) 40.2 65.5 69.5 59.5
Sex (F:M) 10:10 10:8 10:6 0:2
NIHSSa – 8 8 –
GCSa 15 15 14 15
No. 20 18 16 2
SD standard deviation
a On admission
Fig. 1 Serum NfHSMI35 and
S100B in hyperacute stroke
(\24 h from onset of
symptoms). Box-whisker plots
indicate minimum, median, max
and the 25th and 75th
percentiles. The horizontal bar
in the dot-plot diagrams depicts
the mean. n.s. not significant
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Discussion
This study found an extracranial increase in venous blood
of NfHSMI35, a specific marker for axonal injury, degen-
eration and neuronal loss, already present in the very early
course of acute stroke. Serum levels of NfHSMI35 became
detectable within 24 h of symptom onset, an observation
which was also verified within in the 6 h post-stroke time
frame. These findings corroborate recent data in an
experimental piglet model of global brain ischaemia due to
circulatory arrest. The peak of NfHSMI35 serum level was
already detected within 30 min after a 60 min course of
global hypoxia [14]. The findings also extend the obser-
vation of reduced and disrupted NfH staining (NfHSMI31
and silver staining) in the ischaemic hemisphere in exper-
imental focal ischaemia starting at 1–3 days post insult
[18]. Indeed, NfHSMI35 was shown to be a sensitive marker
and even subtle brain injury due to symptomatic carotid
stenosis was associated with 2.4-fold higher NfHSMI35
serum levels compared to asymptomatic carotid stenosis
[15]. Hence, it is tempting to speculate that increased
serum levels of NfHSMI35 reflect the respective acute
neuro-axonal damage evidenced on neuroimaging. Such
information would also be important for targeted man-
agement of stroke patients in future treatment trials. Hence,
a correlation of early NfHSMI35 levels with a sensitive
neuroimaging measure would be one of the next steps.
Final infarct size is determined by a combination of the
initial ischaemic injury and delayed responses to the
ischaemia. The latter include a number of mechanisms
such as inflammatory reactions and apoptosis, which con-
tribute to the overall brain injury [19]. This process evolves
over several days and even weeks post-stroke. In keeping
with this concept, Foerch and coworkers reported that
serum 100B levels assessed within the early stages of
stroke onset did not reflect infarct size [20]. This finding is
also supported by several reports that S100B levels only
correlate with final infarct volume if determined [24 h
after symptom onset [6, 7, 21]. Thus, Foerch et al. argued
that early S100B levels may be regarded more as qualita-
tive measure of blood–brain barrier (BBB) leakage. We are
hesitant to subscribe the findings to a leakage of the BBB
since this is not a precondition of increased blood con-
centrations of biomarkers for brain damage [22]. We pre-
viously reported a median NfHSMI35 concentration of
0.21 ng/mL in CSF of a biologically representative popu-
lation recruited from the UCLH Emergency and Accident
Department. This exceeds the amount found in serum by
far, where NfHSMI35 levels were below the detection limit
in a group of healthy volunteers [23]. Further knowledge
on release, kinetics and clearance of NfH across the body
fluid compartments is required.
Singh et al. did not find significantly increased NfH
values on day 1 compared to controls [11], but did not
report hourly timing from stroke onset and their samples
may have been taken later than in the present study.
Additionally, methodological differences may apply as the
analytical sensitivity in not known. Finally, our study
comprised more severely affected patients with a median
NIHSS of 8 compared to the 6 in the Singh et al. study.
Therefore our patients are likely to have more substantial
brain damage as the source for the serum NfH levels we
measured. These issues may have accounted for the
detectability of NfHSMI35 in the hyperacute phase of stroke.
Compared to healthy controls, Singh reported a 2.9- and
8.5-fold increase after 1 and 3 weeks, respectively. The
further increase at the 3 weeks time point is particularly
intriguing since the observation may correspond to addi-
tional neuro-axonal injury induced by post-stroke immune
and inflammatory processes. We confirm previous studies
that S100B is detectable very early in the course of stroke
and peaks within 1 week in nonfibrinolytic-treated stroke
patients [7, 24, 25]. Yet, S100B in our study did not differ
from the control group, which could be traced back to the
small sample size. In contrast, GFAP could not be detected
over the entire study period. In this regard, Herrmann and
coworkers reported that GFAP becomes detectable
24–72 h post-stroke, and steadily increases and peaks
between 48 and 96 h [24].
In conclusion, this pilot study demonstrated that
NfHSMI35 levels become detectable in the hyperacute phase
of stroke. Differences in the early NfHSMI35 release pattern
Table 2 The longitudinal profile of serum NfHSMI35 (ng/mL) and S100B (ng/mL) levels in stroke patients
Time (hours) after stroke
\6 h 6–24 h 2 days 3 days 4 days 5 days 6 days
No. 8 7 10 7 8 11 10
NfHSMI35 0.14 (0–0.14) 0.14 (0–0.07) 0.13 (0–0.13) 0.09 (0–0.09) 0.14 (0–0.14) 0.13 (0–0.14) 0.13 (0–0.13)
S100B 0.01 (0–0.17) 0.02 (0–0.34) 0.01 (0–0.33) 0.03 (0–0.38) 0.03 (0–0.6) 0.04 (0–0.59) 0.05 (0–0.15)
GFAP – – – – – – –
NfHSMI35 becomes detectable already after 6 h from symptom onset. GFAP was below the detection limit at all time points. Median and range
(brackets) are shown. Statistical analysis did not reveal significant changes over time
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in ischaemic and haemorrhagic stroke could not be evalu-
ated due to only two patients with the latter stroke entity.
Further limitations include the small sample size, and lack
of stratification for stroke localization (e.g. vascular terri-
tory, cortical vs. subcortical) and cause of ischaemic stroke.
Indeed, biomarkers released by cortical pathology are
likely to be found quicker and at higher concentration in
the bloodstream due to diffusion through the cortical
arachnoid villi [22]. Potential factors influencing NfH
release include systemic blood pressure, haemodilution and
brain temperature [26]. Glucose metabolism and glutamate
toxicity are additional factors which could influence NfH
release in the setting of cerebral ischemia. While no post-
hoc adjustments were possible due to the small sample
size, these factors were closely monitored and variations
kept at a minimum. The issues should be considered for the
set-up of further studies aimed at refining the potential
value and different time windows of serum NfHSMI35 in
future stroke management.
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